Krystal Biotech, Inc.
KRYSNext catalyst
KB803
Dystrophic Epidermolysis Bullosa
Get an email about KRYS's next catalysts
Track Krystal Biotech (KRYS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout).See the timeline
4 upcoming, 1 past
KB801 Phase 2 Est. Readout (EMERALD-1)
Primary completion for KB801 trial (NCT06999733) in Neurotrophic Keratitis
SourceKB803 Phase 3 Est. Readout (IOLITE)
Primary completion for KB803 trial (NCT07016750) in Dystrophic Epidermolysis Bullosa
SourceKB707 Phase 2 Est. Readout (KYANITE-1)
Primary completion for KB707 trial (NCT06228326) in Lung Cancer, Non-small Cell
SourceKB707 Phase 2 Est. Readout
Primary completion for KB707 trial (NCT05970497) in Cancer
SourceMarket Overview
Stock performance and key metrics
Open Label Topical Beremagene Geperpavec (B-VEC)
Dystrophic Epidermolysis Bullosa
Topical beremagene geperpavec
Dystrophic Epidermolysis Bullosa
KB803
Dystrophic Epidermolysis Bullosa
KB801
Neurotrophic Keratitis
Opdualag
Cancer
KB707
Lung Cancer, Non-small Cell
KB304
Wrinkles in Decolletage
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open Label Topical Beremagene Geperpavec (B-VEC) | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
Topical beremagene geperpavec | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
KB803 | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
KB801 | Phase 2 | Neurotrophic Keratitis | - | - |
Opdualag | Phase 2 | Cancer | - | - |
KB707 | Phase 2 | Lung Cancer, Non-small Cell | - | - |
KB304 | Phase 2 | Wrinkles in Decolletage | - | - |
Dystrophic Epidermolysis Bullosa
3 drugs in this indication
Lung Cancer, Non-small Cell
1 drug in this indication
Neurotrophic Keratitis
1 drug in this indication
Wrinkles in Decolletage
1 drug in this indication
Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Krystal Biotech, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Krystal Biotech, Inc.'s (KRYS) pipeline across Phase 3, Phase 2. Its lead program is KB803 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Krystal Biotech, Inc.'s next FDA catalyst?→
Krystal Biotech, Inc.'s (KRYS) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KRYS biotech catalysts?→
Add KRYS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Krystal Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
